



(51) International Patent Classification:

C07D 401/14 (2006.01) A61K 31/4196 (2006.01)
 C07D 403/12 (2006.01) A61K 31/422 (2006.01)
 C07D 403/14 (2006.01) A61K 31/4245 (2006.01)
 C07D 405/14 (2006.01) A61K 31/427 (2006.01)
 C07D 409/14 (2006.01) A61K 31/4439 (2006.01)
 C07D 413/14 (2006.01) A61K 31/4375 (2006.01)
 C07D 417/14 (2006.01) A61K 31/454 (2006.01)
 C07D 471/04 (2006.01) A61K 31/496 (2006.01)
 C07D 487/04 (2006.01) A61K 31/497 (2006.01)
 C07D 491/04 (2006.01) A61K 31/506 (2006.01)
 C07D 495/04 (2006.01) A61K 31/5377 (2006.01)
 A61K 31/4155 (2006.01) A61P 25/28 (2006.01)
 A61K 31/4162 (2006.01) A61P 29/02 (2006.01)
 A61K 31/4178 (2006.01) A61P 35/00 (2006.01)
 A61K 31/4192 (2006.01) A61P 33/00 (2006.01)

(21) International Application Number:

PCT/US2012/037003

(22) International Filing Date:

9 May 2012 (09.05.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/485,858 13 May 2011 (13.05.2011) US


(71) Applicant (for all designated States except US): **ARRAY BIOPHARMA INC.** [US/US]; 3200 Walnut Street, Boulder, Colorado 80301 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ALLEN, Shelley** [GB/US]; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **ANDREWS, Steven, W.** [US/US]; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **BLAKE, James, F.** [US/US]; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **CONDROSKI, Kevin, R.** [US/US]; 344 Main Street, Unit B1, Wallingford, Connecticut 06492 (US). **HAAS, Julia** [US/US]; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **HUANG, Lily** [US/US]; 6104 John Chisum Lane, Austin, Texas 78749 (US). **JIANG, Yutong**

[Continued on next page]

(54) Title: PYRROLIDINYL UREA AND PYRROLIDINYL THIOUREA COMPOUNDS AS TRKA KINASE INHIBITORS



(57) Abstract: Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R^1 , R^2 , R^a , R^b , R^c , R^d , X , Y , B , and Ring C are as defined herein, and wherein the $Y-B$ moiety and the $NH-C(=X)-NH$ moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.



[US/US]; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **KERCHER, Timothy** [US/US]; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **KOLAKOWSKI, Gabrielle R.** [US/US]; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **SEO, Jeongbeob** [KR/US]; 11 Ironwood Circle, Baltimore, Maryland 21209 (US).

(74) **Agents:** **HARRIS, Robert, J.** et al.; Viksnins Harris & Padys PLLP, P.O. Box 111098, St. Paul, MN 55111-1098 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))